BIIB068

BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC50 of 1 nM and a Kd of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research[1].

Product Specifications

CAS Number

[1798787-27-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/biib068.html

Concentration

10mM

Purity

99.69

Solubility

DMSO : 31.25 mg/mL (ultrasonic)

Smiles

O=C(N1CC(OC(C)C)C1)NCC2=CC=C(C3=NC(NC4=CN(C)N=C4)=NC=C3)C=C2C

Molecular Formula

C23H29N7O2

Molecular Weight

435.52

Precautions

H302, H315, H319

References & Citations

[1]Bin Ma, Tonika Bohnert, et al. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. J Med Chem. 2020 Jul 22.